XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 28, 2024
Dec. 29, 2023
Current assets:    
Cash and cash equivalents $ 198,459 $ 262,994
Short-term investments 803,540 732,308
Trade receivables, net 396,584 237,407
Inventory 20,614 17,323
Prepaid expenses and other current assets 58,247 67,926
Total current assets 1,477,444 1,317,958
Long-term investments 432,305 728,717
Property and equipment, net 130,210 128,731
Deferred tax assets, net 361,561 361,145
Goodwill 63,684 63,684
Right-of-use assets and other non-current assets 307,917 342,122
Total assets 2,773,121 2,942,357
Current liabilities:    
Accounts payable 28,676 33,768
Accrued compensation and benefits 71,806 93,325
Accrued clinical trial liabilities 64,829 71,615
Rebates and fees due to customers 58,468 59,619
Accrued collaboration liabilities 18,683 27,533
Other current liabilities 103,241 108,417
Total current liabilities 345,703 394,277
Long-term portion of operating lease liabilities 198,017 189,944
Other long-term liabilities 109,667 94,224
Total liabilities 653,387 678,445
Commitments and contingencies (Note 10)
Stockholders' equity:    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 285,222 and 302,793 at June 30, 2024, and December 31, 2023, respectively 285 303
Additional paid-in capital 2,324,570 2,440,710
Accumulated other comprehensive loss (5,149) (3,750)
Accumulated deficit (199,972) (173,351)
Total stockholders’ equity 2,119,734 2,263,912
Total liabilities and stockholders' equity $ 2,773,121 $ 2,942,357